MedMira Reports Second Quarter Results FY2024 - Seite 2

• Assets: The Company recorded a decrease of its assets by $120,828 between Q1 FY2024 and Q2 FY2024 which was mainly due depreciation on fixed assets.
• Liabilities: The Company's liabilities increased by $148,591 between Q1 FY2024 and Q2 FY2024. The Company's current liabilities increased by $445,828 was mainly due to increase in advances.
• Loans in default decreased by $36,791 or 1% compared to last quarter. All other long and short terms debts are currently under negotiation to restructure terms and conditions of repayment.
• Working Capital deficit: As a result of the changes noted above, the Company recorded a higher working capital deficit of $513,163 or 3% compared to last quarter.

The Company's financial statements and management's discussion and analysis are available on the Company's profile on SEDAR at www.sedar.com. For matters of going concern, reference is made to the Auditor's Emphasis of Matter statement in the fiscal year ended 2023 Auditors Report and note 2b in the audited financial statements which are also available on SEDAR.

About MedMira

MedMira is the developer and owner of Rapid Vertical Flow (RVF) Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal, Multiplo and Miriad brands in global markets. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has a sales and customer service office located in the United States. For more information visit medmira.com. Follow us on Twitter and LinkedIn.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

MedMira Contacts:

Markus Meile, CFO
Tel: [phone]
Email: [e-mail]

SOURCE: MedMira

View the original press release on accesswire.com


The Medmira Stock at the time of publication of the news with a raise of 0,00 % to 0,085EUR on TSX Venture stock exchange (01. April 2024, 21:52 Uhr).